共 48 条
[1]
Filippi S(2007)Characterization and functional role of androgen-dependent PDE5 activity in the bladder Endocrinology 148 1019-1029
[2]
Morelli A(1995)Pathophysiology of clinical benign prostatic hyperplasia Urol Clin N Am 22 285-290
[3]
Sandner P(2011)Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action Neurourol Urodyn 30 292-301
[4]
Shapiro E(2003)The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study BJU Int 92 719-725
[5]
Lepor H(2002)Sildenafil influences lower urinary tract symptoms BJU Int 90 836-839
[6]
Andersson KE(2007)Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 1071-1077
[7]
de Groat WC(2008)Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study J Urol 180 1228-1234
[8]
McVary KT(2008)A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 1236-1244
[9]
Boyle P(2003)Chapter 1: diagnosis and treatment recommendations J Urol 170 530-547
[10]
Robertson C(2009)Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue J Sex Med 6 836-847